BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3545428)

  • 1. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia.
    Zander AR; Culbert S; Jagannath S; Spitzer G; Keating M; Larry N; Cockerill K; Hester J; Horwitz L; Vellekoop L
    Cancer; 1987 Mar; 59(6):1083-6. PubMed ID: 3545428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
    Ikuta K; Fujioka K; Sumita H; Takahashi H; Sekiguchi H; Kai S; Kajigaya Y; Funabiki T; Sakai H; Matsuyama S
    Rinsho Ketsueki; 1993 May; 34(5):636-42. PubMed ID: 8100284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
    Giralt SA; LeMaistre CF; Vriesendorp HM; Andersson BS; Dimopoulos M; Gajewski J; Van Besien K; Mehra R; Przepiorka D; Khouri I
    J Clin Oncol; 1994 Sep; 12(9):1923-30. PubMed ID: 8083714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
    Vellekoop L; Jagannath S; Spitzer G; Zander AR; Horwitz LJ; Keating M; McCredie KB; Dicke KA
    Am J Clin Oncol; 1986 Aug; 9(4):307-10. PubMed ID: 3529919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
    Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
    J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.
    Vellekoop L; Dicke KA; Zander AR; Spitzer G; Verma DS; Keating MM; McCredie KB
    Eur J Cancer Clin Oncol; 1984 May; 20(5):593-9. PubMed ID: 6376130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
    Kantarjian HM; Walters RS; Keating MJ; Smith TL; O'Brien S; Estey EH; Huh YO; Spinolo J; Dicke K; Barlogie B
    J Clin Oncol; 1990 Jun; 8(6):994-1004. PubMed ID: 2189958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
    Santos GW; Tutschka PJ; Brookmeyer R; Saral R; Beschorner WE; Bias WB; Braine HG; Burns WH; Elfenbein GJ; Kaizer H
    N Engl J Med; 1983 Dec; 309(22):1347-53. PubMed ID: 6355849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group.
    Brown RA; Wolff SN; Fay JW; Pineiro L; Collins RH; Lynch JP; Stevens D; Greer J; Herzig RH; Herzig GP
    Leuk Lymphoma; 1996 Jul; 22(3-4):271-7. PubMed ID: 8819076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.